AstraZeneca (AZ) has reportedly made a bid of about USD 10 billion for Rhythm Pharmaceuticals, with a non-binding proposal of up to USD 134 per share including milestone payments, led by its Alexion rare-disease unit. Rhythm shares rose 28% to USD 110.68 on the news and have continued climbing, giving the company a market value near USD 7.9 billion, while analysts at Jefferies, Leerink Partners and William Blair suggest competing bids could emerge given Imcivree peak sales estimates above USD 2 billion across current indications.
The strategic logic rests on Rhythm's MC4R pathway franchise. Imcivree, approved since 2020 for genetic obesity disorders including POMC, PCSK1 and LEPR deficiency and Bardet-Biedl syndrome, gained US approval in March for acquired hypothalamic obesity after the Phase III TRANSCEND trial showed a placebo-adjusted BMI reduction of 18.4%, and third-quarter sales reached USD 67.5 million in the US and USD 92.1 million globally, with nine-month product revenue of USD 223.5 million, up 63%.
With next-generation oral MC4R agonists bivamelagon and RM-178 advancing, Rhythm offers AZ a differentiated specialist platform in obesity that sidesteps crowded GLP-1 competition.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation